Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: zandant, LilKahuna, BooDog, TheHound, scottsmith, Lemoncat
Search This Board: 
Last Post: 5/25/2019 1:36:03 PM - Followers: 754 - Board type: Free - Posts Today: 17

Innovation Pharmaceuticals Inc. (IPIX)

SEC Filings  https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management:  http://www.ipharminc.com/senior-management/

Scientific Advisors:  http://www.ipharminc.com/scientific-advisors/

Clinical Trials:  https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name:   https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps

 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

PIPELINE: 
CLICK TO VIEW LARGER IMAGE

 

FDA DESIGNATIONS:

 

Stages of development:

stages-v2.jpg


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Innovation Pharmaceuticals IP



Patent Filings:


EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Chart:   https://stockcharts.com/h-sc/ui?s=IPIX

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 05/16/2019 10:16:34 AM
IPIX News: Quarterly Report (10-q) 05/10/2019 05:19:36 PM
IPIX News: Current Report Filing (8-k) 05/10/2019 07:33:24 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/10/2019 07:32:13 AM
IPIX News: Quarterly Report (10-q) 02/08/2019 04:05:27 PM
PlusOneCoin Top Posts
#264131   IPIX is building momentum to formulate an oral farrell90 05/21/19 11:49:22 PM
#253731   “The Misleading” – Daily Short Volume sox040713 01/08/19 08:51:48 PM
#263714   The term sheet news is very positive. I farrell90 05/17/19 02:27:41 PM
PostSubject
#263597  Sticky Note I believe both term sheets are under the BooDog 05/17/19 05:35:35 AM
#253731  Sticky Note “The Misleading” – Daily Short Volume sox040713 01/08/19 08:51:48 PM
#253439  Sticky Note Prurisol Results Released -- See Link Below scottsmith 01/04/19 04:41:27 PM
#253363  Sticky Note Sometimes it helps to looks at some of Lemoncat 01/03/19 09:06:01 PM
#249866  Sticky Note BOARD WARNING: Please read - IH Admin [Shelly] 11/26/18 10:31:07 AM
#264400   Prioritizing prurisol over brilacidin was a terrible call scottsmith 05/25/19 01:22:28 PM
#264399   Prurisol had stellar preclinical results. Phase 2a showed Lemoncat 05/25/19 01:02:54 PM
#264398   YES! Just stick to that.. and most longs won't cybermich 05/25/19 01:01:06 PM
#264396   Like Prurisol is junk science? It failed. That scottsmith 05/25/19 12:34:21 PM
#264395   bearish hammer on the week MXAMDUD 05/25/19 12:28:46 PM
#264394   This just shows support that investors believe things bejamin 05/25/19 12:07:17 PM
#264393   let's see: worth billions if B and To infinity and beyond! 05/25/19 10:58:02 AM
#264392   So 1hb, any updates on your prognosticators? Could snayeman 05/25/19 10:46:15 AM
#264391   All depends how quick and successful future trials Lemoncat 05/25/19 09:00:27 AM
#264390   Ten years then? Is there no circumstance that TheDane 05/25/19 08:34:44 AM
#264389   Wasn't that said 5 years ago? Blues44 05/25/19 07:33:12 AM
#264388   How about with a five year projection? TheDane 05/25/19 07:30:48 AM
#264387   Nonsense is $50 price predictions. Blues44 05/25/19 06:29:24 AM
#264386   guess what- we will all get a ringside To infinity and beyond! 05/25/19 12:04:58 AM
#264385   Considering how accurate your other "guesses" about price cybermich 05/24/19 11:46:11 PM
#264384   That’s nonsense. The price is yet to reflect LilKahuna 05/24/19 09:34:24 PM
#264380   Sorry folks, deal already priced in at 30 To infinity and beyond! 05/24/19 09:04:10 PM
#264378   plenty of disappointment to go around when it To infinity and beyond! 05/24/19 08:38:12 PM
#264377   “For that to happen it would mean it’s kfcyahoo 05/24/19 08:26:30 PM
#264376   Well all, have a great Memorial Day weekend. LilKahuna 05/24/19 07:52:52 PM
#264370   FINRA short sales of IPIX AlanC 05/24/19 05:38:25 PM
#264369   Another good week for IPIX:) cybermich 05/24/19 05:34:02 PM
#264368   Congratulation on your election to moderator. Well scottsmith 05/24/19 05:03:09 PM
#264367   I’m not so sure about that since look Here Today 05/24/19 04:45:18 PM
#264366   I haven’t looked at the chart but I TheDane 05/24/19 04:41:48 PM
#264365   .27 close. Perfect! TheDane 05/24/19 04:24:43 PM
#264364   Looking ok. At least 5 continuous weeks zandant 05/24/19 04:20:24 PM
#264363   excellent 299 share paint job at the close. krobar 05/24/19 04:02:10 PM
#264362   For that to happen it would mean it’s TheDane 05/24/19 03:35:39 PM
#264361   Have a great weekend. Let's see if zandant 05/24/19 02:37:26 PM
#264360   Pete, it is a good question. A better farrell90 05/24/19 02:27:31 PM
#264359   There is no getting ahead. All I stated Here Today 05/24/19 02:16:44 PM
#264358   Yes I see. Williamsc 05/24/19 02:08:06 PM
#264357   P or Prurisol was a failure. That’s part madmarkie 05/24/19 02:02:48 PM
#264356   There wasn't, just keeping up with the negative narrative leavetheguntakethecannolis 05/24/19 02:01:23 PM
#264355   Signed term sheet for "P".?? When was that. Williamsc 05/24/19 01:51:33 PM
#264354   Come on 30! Green weekend snayeman 05/24/19 01:40:37 PM
#264353   Just like the signed term sheet for "P", JTORENCE 05/24/19 01:28:31 PM
#264352   A signed deal could come out of no Williamsc 05/24/19 01:20:53 PM
#264351   We may be getting ahead of ourselves. zandant 05/24/19 01:07:46 PM
#264350   HA What happened to decades to death. Williamsc 05/24/19 01:05:45 PM
#264349   Would be great seeing on Tuesday morning an Here Today 05/24/19 12:57:26 PM
#264348  Restored Wrong again:) cybermich 05/24/19 12:52:06 PM
#264343   Ready for the next leg into the .50's. BooDog 05/24/19 11:58:26 AM
#264342   We will have a chance to find out To infinity and beyond! 05/24/19 11:54:32 AM
#264340   Good one. The volume is better than expected. TheDane 05/24/19 11:38:28 AM
#264339   going lower - filling buys on the .25 bid. MXAMDUD 05/24/19 11:27:15 AM
#264338   I called this .25 walkdown yesterday. red hammer. MXAMDUD 05/24/19 11:02:51 AM
#264337   Investing in IPIX is a GAMBLE - Gentleman’s madmarkie 05/24/19 10:43:06 AM
#264336   It's only priced in if we have a Lemoncat 05/24/19 10:41:19 AM
PostSubject